Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2025 17:43 ET | Source: Bragar Eagel & Squire

AVITA MEDICAL INVESTIGATION: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders

Avita allegedly revealed unpaid claim backlogs for Recell procedures, causing provider uncertainty and a 21% stock drop on August 8, 2025.
October 09, 2025 12:49 ET | Source: Bragar Eagel & Squire

AVITA REMINDER: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders

Avita revealed a six-month backlog of unpaid Recell claims due to CMS pricing delays, hurting demand and driving shares down 21% to $4.25 on August 8, 2025
October 03, 2025 07:45 ET | Source: Bragar Eagel & Squire

AVITA (RCEL) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into AVITA Medical, Inc. and Encourages Investors to Contact the Firm

Avita revealed CMS pricing delays caused a 6-month backlog in unpaid Recell claims, hurting demand; shares fell 21% to $4.25 on Aug 8, 2025.
September 25, 2025 17:24 ET | Source: Bragar Eagel & Squire

AVITA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm

Avita revealed a six-month backlog of unpaid Recell claims, hurting demand. Shares fell $1.13, or 21%, from $5.38 on Aug 7 to $4.25 on Aug 8, 2025.
September 15, 2025 17:45 ET | Source: Bragar Eagel & Squire

AVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm

Avita stock dropped 21% after Q2 2025 results revealed CMS pricing delays caused a six-month backlog of unpaid Recell claims.
September 08, 2025 17:13 ET | Source: Bragar Eagel & Squire

AVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm

On Aug 7, 2025, Avita revealed a 6-month Recell claims backlog that hurt demand; shares fell 21% to $4.25.
September 04, 2025 08:25 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Is Investigating Avita, Coty, and Sensus and Encourages Investors to Contact the Firm

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AVITA Medical, Inc....
August 27, 2025 16:02 ET | Source: Bragar Eagel & Squire

AVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm

On August 8, 2025, Avita shares fell 21% to $4.25 after revealing unpaid Recell claims caused a demand drop due to CMS pricing and adjudication delays.
August 06, 2025 16:05 ET | Source: AVITA Medical

AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance

AVITA Medical appoints Dr. Michael Tarnoff to Board. Cary Vance becomes Board Chair, replacing Lou Panaccio. Strengthens acute wound care focus